Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Cmte. Package Redaction Could Add Two Months To Priority Review

Executive Summary

A drug receiving six-month priority review could have its review time extended by up to two months if its sponsor requests redaction of the advisory committee package, FDA said in a draft guidance.
Advertisement

Related Content

Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Celebrex information disclosure
Celebrex information disclosure
FDA Advisory Cmte. Material Disclosure To Debut With Bayer ProMem Review
FDA Advisory Cmte. Material Disclosure To Debut With Bayer ProMem Review
Advertisement
UsernamePublicRestriction

Register

PS035356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel